Allopurinol Tablet
FDA Label NDC 0904-6572

32 label sections · Submitted to the FDA by Major Pharmaceuticals · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Major Pharmaceuticals for the product Allopurinol (NDC 0904-6572). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 recommended testing prior to treatment initiation, 2.2 recommended prophylaxis for gout flares, 2.3 recommended dosage for gout, 2.4 recommended dosage for hyperuricemia associated with cancer therapy, 2.5 recommended dosage for management of recurrent calcium oxalate calculi in hyperuricosuric patients, 2.6 recommended dosage in patients with renal impairment, 3 dosage forms and strengths, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Package/Label Display Panel

MAJOR®

NDC 0904-6572-61

Unit Dose

Allopurinol

Tablets, USP

300 mg

100 TABLETS (10 x 10)

Rx only

300mg Carton Label (14909994 D957 4d81 A6e6 68d64107fd1b 00)

300mg Carton Label (14909994 D957 4d81 A6e6 68d64107fd1b 00)

* Please review the disclaimer below.